版本:
中国

BRIEF-Redhill Biopharma announces peer-reviewed publication of positive Yeliva® phase I study results in advanced solid tumors

April 20 Redhill Biopharma Ltd

* Redhill biopharma announces peer-reviewed publication of the positive yeliva® phase i study results in advanced solid tumors

* Redhill biopharma ltd says phase i study with yeliva(®) in patients with advanced solid tumors successfully met its primary and secondary endpoints

* Redhill biopharma ltd says results demonstrated that drug is well-tolerated and can be safely administered to cancer patients in study

* Redhill biopharma ltd says is pursuing several phase i/ii clinical studies with yeliva, targeting multiple oncology and inflammatory indications

* Redhill biopharma -phase ii study to evaluate efficacy of yeliva in patients with moderate to severe ulcerative colitis is to be initiated in h2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐